SOX2 and neoplasm: Accumulated evidence indicates that several SOX members have been identified as tumor-specific antigens that can augment cytotoxic T lymphocytes (CTLs) response to kill cancer cells, including SOX2 (glioblastoma) [166], SOX4 (lung cancer) [167], SOX6 (glioblastoma) [168,169], and SOX11 (glioblastoma) [170].